EGFR Isoforms Might be Responsible for the Diminished Treatment Outcome of EGFR Inhibitors
- 1,2*,
- 1,
- 3,
- 3,
- 4,
- 4,
- 4,
- 2
- 1Applied Biosciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.
- 2School of Natural Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.
- 3Macquarie Analytical & Fabrication Facility, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.
- 4Australian Proteome Analysis Facility, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Rajdeep Chakraborty
Applied Biosciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.; School of Natural Sciences, Faculty of Science and Engineering, Macquarie University, Sydney, NSW, AUSTRALIA.
Email: rajdeep.chakraborty@mq.edu.au
Copyright: © 2026 The Author(s). This is an open access article.
Published: Jan 1, 2026, Received: Mar 16, 2024, Accepted: Jan 31, 2025
Abstract
Epidermal growth factor receptor (EGFR) plays an active role during the progression of oral squamous cell carcinoma (OSCC). OSCC is the most common head and neck cancer. Cetuximab, which is an inhibitor of EGFR, was approved by the Food and Drug Administration (FDA) in 2006 for the treatment of head and neck cancer. After initial clinical success, Cetuximab proved to be ineffective in the management of aggressive or metastatic oral cancer lesions. We hypothesize that EGFR has multiple isoforms that lead to the failure of Cetuximab. A future study of EGFR isoforms and protein-interacting partners will address the issue.
Keywords
Subject
Recommended articles
- Assessing the Anticancer Potential of Compounds from Caesalpinia sappan Wood against Mutant EGFR in Lung Squamous Cell Carcinoma: Computational Insights
Shaik Pashmina, Nitya Krishnasamy, Suganya Panneer Selvam · Journal of Pharmacology and Pharmacotherapeutics
- Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review
Christian Leporini, Francesca Saullo, Gianfranco Filippelli · Journal of Pharmacology and Pharmacotherapeutics
Readers Also Viewed
Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models
Annisa Fatharani, Ali Alsayegh
Jan 1, 2026
Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review
Mohammad Akbar Hossain
Jan 1, 2026
Knowledge, Attitude, and Practice on Digital Eye Strain Among Healthcare Students at a Private University in Northern Peninsular Malaysia
Lim Chin Hung, Subramani Parasuraman, Sam Aaseer Thamby
Jan 1, 2026